metabolic-dysfunction-associated fatty liver disease
Conditions
Interventions
Gold Standard:Pathology of liver biopsy or MRI-derived proton density fat fraction
Index test:Ultrasound derived fat fraction
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Chinese patients aged 18-85 years; 2. Patients with diffuse or uneven fatty liver in conventional ultrasound. 3. Accordance with the definition of MAFLD: A positive diagnosis of MAFLD are based on histological (biopsy), imaging or blood biomarker evidence of fat accumulation in the liver (hepatic steatosis) in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. The latter is defined by the presence of at least two metabolic risk abnormalities: (1) Waist circumference >= 90/80 cm in men and women; (2) Blood pressure >= 130/85 mmHg or specific drug treatment; (3) Plasma triglycerides >= 150 mg/dl (>= 1.70 mmol/L) or specific drug treatment; (4) Plasma HDL-cholesterol = 2.5; (7) Plasma high-sensitivity C-reactive protein level > 2 mg/L. 4. Patients who will conduct liver biopsy or MRI-PDFF to evaluate the grade of liver fat within one week of UDFF examination. 5. Patients without bleeding risk (Plate>= 50 x 10^9/L, IRN <= 1.5). 6. Sign the informed consent.
Exclusion criteria
Exclusion criteria: Patients with pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ultrasound derived fat fraction (UDFF); | — |
Secondary
| Measure | Time frame |
|---|---|
| shear wave elastography (SWE); | — |
Countries
China
Contacts
Public ContactHong Ding
Huashan Hospital, Fudan University
Outcome results
None listed